mohd izzuan Regeneron Pharmaceuticals ( NASDAQ: REGN ) is down ~10% in Thursday morning trading despite releasing Q3 financial results that beat on both lines . While the pharma provided some updated guidance, none of it dealt with revenue or earnings. Non-GAAP R&D is now seen at $4.
525B–$4.575B from $4.5B-$4.
6B.